Compare JACK & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JACK | VCYT |
|---|---|---|
| Founded | 1951 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.7M | 2.9B |
| IPO Year | 1987 | 2013 |
| Metric | JACK | VCYT |
|---|---|---|
| Price | $21.09 | $42.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 8 |
| Target Price | $24.06 | ★ $45.38 |
| AVG Volume (30 Days) | ★ 1.1M | 1.0M |
| Earning Date | 11-19-2025 | 11-04-2025 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | ★ $1,465,314,000.00 | $495,141,000.00 |
| Revenue This Year | N/A | $16.02 |
| Revenue Next Year | $0.52 | $10.74 |
| P/E Ratio | ★ N/A | $112.61 |
| Revenue Growth | N/A | ★ 16.41 |
| 52 Week Low | $13.99 | $22.61 |
| 52 Week High | $48.12 | $50.71 |
| Indicator | JACK | VCYT |
|---|---|---|
| Relative Strength Index (RSI) | 69.27 | 50.52 |
| Support Level | $17.98 | $45.68 |
| Resistance Level | $20.06 | $45.17 |
| Average True Range (ATR) | 1.13 | 1.95 |
| MACD | 0.28 | -0.70 |
| Stochastic Oscillator | 91.76 | 16.81 |
Jack In The Box Inc operates quick-service restaurants and fast-casual restaurants across various states in the United States of America under the Jack in the Box and Del Taco brands. The company's menu offers burgers, tacos, regular and curly fries, specialty sandwiches, salads, and ice cream shakes. These foods are available with the option of customization as per customer requirements. The company also offers catering and delivery services to its customers. Jack in the Box and Del Taco restaurant brands are the two reportable operating segments, of which, Jack in the Box generates maximum revenue for the company.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.